A phase II study of NSCLC observed that ipilimumab neoadjuvant therapy had significant CD28-dependent activation of both CD4+ T cells and CD8+ T cells (Yi et al., 2017). This evidence concerns the gene CD4 and non-small cell lung carcinoma.